Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives

DOI: 10.1161/01.hyp.0000224283.76347.8c
Hypertension, 2006, 48, 80-6.

#	Paper	IF	Citations
149	Arterial blood pressure and stiffness in hypertension: is arterial structure important?. *Hypertension*, **2006**, 48, 366-7	8.5	20
148	Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. **2007**, 21, 654-63		25
147	Hypertension and cardiovascular disease: is arterial stiffness the heart of the matter?. **2007**, 16, 236-7		2
146	Recent advances in arterial stiffness and wave reflection in human hypertension. *Hypertension*, **2007**, 49, 1202-6	8.5	203
145	Contribution of perindopril to cardiology: 20 years of success. **2007**, 9, E10-E19		7
144	Improvement of arterial stiffness by aerobic exercise in elderly subjects. **2007**, 30, 875-6		2
143	Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. **2007**, 16, 409-15		20
142	Noninvasive measures of cardiovascular changes in diabetes mellitus. **2007**, 14, 263-8		6
141	Should pulse pressure and day/night variations in blood pressure be seen as independent risk factors requiring correction or simply as markers to be taken into account when evaluating overall vascular risk?. **2007**, 33, 321-30		15
140	Ileostomy and ramipril-induced acute renal failure and shock. **2007**, 36, 298-9		1
139	ACE inhibition in hypertension: focus on perindopril. *American Journal of Cardiovascular Drugs*, **2007** , 7, 303-17	4	15
138	Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials. **2007**, 27, 149-61		5
137	Perindopril: the evidence of its therapeutic impact in hypertension. *Core Evidence*, **2007**, Volume 2, 0-0	4.9	2
136	[Modifications of structural and functional properties of large arteries in diabetes mellitus]. **2007**, 51, 176-84		6
135	Arterial stiffness: is it ready for prime time?. **2007**, 9, 462-9		8
134	Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. **2007**, 63, 733-41		15
133	Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. **2008**, 294, H551-69		66

132	Importance of arterial stiffness as cardiovascular risk factor for future development of new type of drugs. **2008**, 22, 241-6		38
131	Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform. **2008**, 10, 295-303		118
130	Evaluation of aortic stiffness to predict and prevent the risk of atrial fibrillation in hypertensive patients in their 50s. **2008**, 101, 9-10		2
129	Beyond blood pressure: Arterial stiffness as a new biomarker of cardiovascular disease. **2008**, 2, 140-51		42
128	Lowering of brachial pulse pressure in 9379 hypertensives with type 2 diabetes and reduction of cardiovascular events. **2008**, 17, 26-33		4
127	Simultaneous measurement of beat-to-beat carotid diameter and pressure changes to assess arterial mechanical properties. *Hypertension*, **2008**, 52, 896-902	8.5	47
126	Perindopril: beyond lowering blood pressure. **2008**, 4, 219-35		
125	Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. *American Journal of Hypertension*, **2008**, 21, 701-7	2.3	5
124	Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. *Hypertension*, **2008**, 51, 1617-23	8.5	114
123	Carotid plaque, arterial stiffness gradient, and remodeling in hypertension. *Hypertension*, **2008**, 52, 729-36	8.5	49
122	Benefits of perindopril all along the cardiovascular continuum: the level of evidence. **2008**, 10, G4-G12		
121	Bibliography. Current world literature. Circulation and hemodynamics. **2008**, 17, 111-26		
120	Reactive oxygen species and dopamine receptor function in essential hypertension. **2009**, 31, 156-78		31
119	Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention. *Hypertension*, **2009**, 54, 3-10	8.5	231
118	The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. **2009**, 15, 272-89		112
117	Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. **2009**, 23, 307-15		56
116	Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. *Hypertension* , **2009**, 54, 388-92	8.5	149
115	Role of renin-angiotensin system blockade in patients with diabetes mellitus. **2009**, 104, 835-9		32

114	Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. *Current Hypertension Reports*, **2009**, 11, 190-6	4.7	49
113	Antihypertensive drugs and central blood pressure. *Current Hypertension Reports*, **2009**, 11, 253-9	4.7	18
112	Analysis of cardiovascular responses to passive head-up tilt using continuous pulse wave analysis and impedance cardiography. **2009**, 69, 128-37		56
111	Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis. **2009**, 3, 367-78		34
110	The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. *American Journal of Cardiovascular Drugs*, **2009**, 9, 283-91	4	6
109	Direct measurement of wall stiffness for carotid arteries by ultrasound strain imaging. **2009**, 22, 1389-95		34
108	[Angiotensin converting enzyme inhibitors and calcium antagonists: a synergistic action for a better prevention of cardiovascular events]. **2009**, 64, 241-8		1
107	Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. **2009**, 15, 571-84		33
106	Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. *Journal of Hypertension*, **2010**, 28, 2336-41	1.9	72
105	Aging and arterial stiffness. **2010**, 74, 2257-62		380
104	Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?. **2010**, 2, 83-7		
103	Prognostic value of changes in arterial stiffness in men with coronary artery disease. **2010**, 6, 1015-21		26
102	Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. *Hypertension*, **2010**, 55, 1314-22	8.5	168
101	Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. **2010**, 13, 757-68		49
100	Age-independent association between arterial and bone remodeling in mild-to-moderate chronic kidney disease. **2010**, 25, 191-7		9
99	Arterial stiffness: methods of measurement, physiologic determinants and prediction of cardiovascular outcomes. *International Journal of Cardiology*, **2010**, 138, 112-8	3.2	68
98	Hypertrophic remodeling and increased arterial stiffness in patients with intracranial aneurysms. **2010**, 211, 486-91		17
97	Longitudinal changes in central artery stiffness with lifestyle modification, washout, and drug treatment in individuals at risk for cardiovascular disease. **2010**, 8, 323-9		

96	Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. *American Journal of Cardiovascular Drugs*, **2011**, 11, 45-55	4	18
95	Pharmacological modulation of arterial stiffness. **2011**, 71, 1689-701		99
94	Perindopril for the treatment of hypertension. **2011**, 12, 1633-42		6
93	ADVANCES IN ARTERIAL STIFFNESS ASSESSMENT. *Artery Research*, **2011**, 5, 130	2.2	7
92	The effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension. **2011**, 35, 236-42		7
91	Vascular compliance in blood pressure. **2011**, 20, 457-64		21
90	Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. *Journal of Hypertension*, **2011**, 29, 1034-42	1.9	174
89	Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials. **2011**, 25, 395-404		20
88	Paris Prospective Study III: a study of novel heart rate parameters, baroreflex sensitivity and risk of sudden death. **2011**, 26, 887-92		37
87	Early vascular aging and the role of central blood pressure. *Journal of Hypertension*, **2011**, 29, 1847-53	1.9	79
86	RAS blockade for every diabetic patient: pro and con. **2011**, 34 Suppl 2, S320-4		10
85	Arterial remodeling associates with CKD progression. **2011**, 22, 967-74		115
84	Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. **2012**, 19, 43-54		8
83	Arterial stiffness as surrogate end point: needed clinical trials. *Hypertension*, **2012**, 60, 518-22	8.5	77
82	Chronic reduction of nitric oxide level in adult spontaneously hypertensive rats induces aortic stiffness similar to old spontaneously hypertensive rats. **2012**, 49, 309-18		33
81	Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. *European Heart Journal*, **2012**, 33, 1530-8	9.5	48
80	Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control?. **2012**, 18, 1011-20		7
79	Arterial stiffness is associated with tissue Doppler atrial conduction times and P wave dispersion in hypertensive patients. **2012**, 51, 147-53		5

78	Aortic stiffness predicts functional outcome in patients after ischemic stroke. **2012**, 43, 543-4		57
77	Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage/alterations. **2012**, 31, 1132-43		15
76	Role of antihypertensive drugs in arterial Side-stiffeningSand central pulsatile hemodynamics. *American Journal of Cardiovascular Drugs*, **2012**, 12, 143-56	4	35
75	Mechanisms of arterial remodeling: lessons from genetic diseases. **2012**, 3, 290		81
74	Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention. **2012**, 14, 433-42		21
73	The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. **2013**, 11, 705-17		35
72	Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. **2013**, 33, 553-61		34
71	Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. **2013**, 18, 429-37		17
70	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. *Journal of Hypertension*, **2013**, 31, 1893-900	1.9	57
69	Current and future initiatives for vascular health management in clinical practice. **2013**, 9, 255-64		8
68	Arterial Stiffness: A Review in Type 2 Diabetes. **2013**,		
67	Perindopril for improving cardiovascular events. **2014**, 10, 539-48		1
66	Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. *Hypertension*, **2014**, 64, 709-16	8.5	72
65	Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study. **2014**, 19, 294-301		5
64	Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. *Journal of Hypertension*, **2014**, 32, 108-14	1.9	23
63	Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. *Current Hypertension Reports*, **2014**, 16, 479	4.7	16
62	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. **2014**,		16
61	The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy. **2015**, 16, 597-602		18

60	Early Vascular Aging: A New Target for Hypertension Treatment. **2016**, 22, 122-6		12
59	RAS inhibitorsSdose-dependent efficacy: myth or reality?. *Current Medical Research and Opinion*, **2015**, 31, 1245-56	2.5	11
58	Targeting Central Blood Pressure Through the Macro- and Microcirculation Cross-Talk. **2015**, 297-307		3
57	Targeting Blood Pressure Lowering and the Sympathetic Nervous System. **2015**, 287-296		
56	Spinal NF-B and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. **2015**, 10, e0115120		26
55	Assessment of Preclinical Organ Damage in Hypertension. **2015**,		1
54	Continuous-Flow Circulatory Support: The Achilles Heel of Current-Generation Left Ventricular Assist Devices?. **2015**, 8, 850-2		6
53	Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. **2015**, 22, 417-25		9
52	Pulse Wave Velocity and Central Blood Pressure. **2015**, 63-73		
51	Renal Denervation. **2015**,		2
50	Arterial Destiffening in Previously Untreated Mild Hypertensives After 1 Year of Routine Clinical Management. *American Journal of Hypertension*, **2017**, 30, 510-517	2.3	13
49	New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease. *Current Hypertension Reports*, **2016**, 18, 55	4.7	5
48	Renal denervation: a blunt weapon against isolated systolic hypertension?. *European Heart Journal*, **2017**, 38, 101-103	9.5	4
47	Dose-effect relationship of perindopril 10, 14 and 20mg assessed by urine and plasma AcSDKP levels in mildly sodium-depleted healthy volunteers. *International Journal of Cardiology*, **2016**, 222, 648-653	3.2	2
46	Arterial Stiffness: Going a Step Beyond. *American Journal of Hypertension*, **2016**, 29, 1223-1233	2.3	47
45	Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity. *American Journal of Cardiovascular Drugs*, **2016**, 16, 309-21	4	43
44	SIRT1 in Endothelial Cells as a Novel Target for the Prevention of Early Vascular Aging. *Journal of Cardiovascular Pharmacology*, **2016**, 67, 465-73	3.1	30
43	Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes. *American Journal of Hypertension*, **2016**, 29, 1055-62	2.3	7

42	The effects of antihypertensive drugs on arterial stiffness?. *Artery Research*, **2016**, 14, 1	2.2	2
41	Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. A meta-analysis of 13 randomized controlled trials. *Herz*, **2016**, 41, 76-86	2.6	14
40	Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment. *Current Hypertension Reports*, **2017**, 19, 2	4.7	20
39	Antihypertensive treatment-induced changes in arterial stiffness: Which artery? Which method?. *Journal of Hypertension*, **2017**, 35, 721-725	1.9	3
38	Vascular Smooth Muscle Cells and Arterial Stiffening: Relevance in Development, Aging, and Disease. *Physiological Reviews*, **2017**, 97, 1555-1617	47.9	272
37	Antihypertensive drugs. *Pharmacological Research*, **2017**, 124, 116-125	10.2	104
36	Patient Management of Hypertensive Subjects without and with Diabetes Mellitus Type II. *Medical Clinics of North America*, **2017**, 101, 159-167	7	1
35	Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes. *Current Medical Research and Opinion*, **2018**, 34, 1557-1570	2.5	2
34	A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril. *Cardiology and Therapy*, **2019**, 8, 179-191	2.8	25
33	Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study. *American Journal of Hypertension*, **2019**, 32, 992-1002	2.3	4
32	Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension. *Hypertension*, **2019**, 73, 1138-1149	8.5	51
31	Hypertension and Target Organ Damage. **2019**, 406-414		
30	The Clinical Significance and Application of Vascular Stiffness Measurements. *American Journal of Hypertension*, **2019**, 32, 4-11	2.3	17
29	Comparative effects of enalapril versus perindopril on serum levels of leptin and adiponectin in hypertensive patients. *Acta Cardiologica*, **2020**, 75, 551-556	0.9	2
28	Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study. *Journal of the American Heart Association*, **2020** , 9, e017018	6	4
27	Arterial Stiffness and Hypertension in the Elderly. *Frontiers in Cardiovascular Medicine*, **2020**, 7, 544302	5.4	20
26	Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial. *Advances in Therapy*, **2020**, 37, 3551-3561	4.1	5
25	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. *Microvascular Research*, **2020**, 129, 103974	3.7	7

24	Arterial Stiffness and Cardiovascular Risk in Hypertension. *Circulation Research*, **2021**, 128, 864-886	15.7	32
23	The impact of various antihypertensive medications on vascular aging. *Arterial Hypertension (Russian Federation)*, **2021**, 27, 133-145	0.7	
22	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. *Hypertension*, **2021**, 78, 983-995	8.5	13
21	Role of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril. *Klinicist*, **2021**, 14, 78-85	0.3	0
20	Antihypertensive Drugs. **2012**, 1824-1878		1
19	ADDITIONAL ANGIOPROTECTION AND METABOLIC DISORDERS CORRECTION IN TREATMENT OF ARTERIAL HYPERTENSION PATIENTS REACHED TARGET BLOOD PRESSURE LEVELS, WITH FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE. *Russian Journal of Cardiology*, **2018**, 67-74	1.3	1
18	Vascular ageing: main symptoms and mechanisms. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2012**, 11, 93-100	0.9	17
17	A COMPARISON OF THE MAIN ANTIHYPERTENSIVE DRUGS FROM THE VIEWPOINT OF AORTIC STIFFNESS MODIFICATION IN ARTERIAL HYPERTENSION. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2014**, 13, 76-79	0.9	2
16	Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. *Arterial Hypertension (Russian Federation)*, **2018**, 24, 369-378	0.7	1
15	Effects of Angiotensin-Converting Enzyme Inhibitor on Arterial Stiffness, Diastolic Function, and Exercise Performance in Patients with Hypertension. *Journal of the Korean Geriatrics Society*, **2009**, 13, 7-15		
14	Association of functioning systems in pathogenesis of hypertension. *Arterial Hypertension (Russian Federation)*, **2010**, 16, 325-332	0.7	
13	Decreasing Arterial Stiffness and/or Wave Reflections Independently of Mean Arterial Pressure: Effect of Antihypertensive Drugs (Part 1). **2014**, 475-485		
12	The Endpoint on Measuring the Clinical Effects of Renal Denervation: What Are the Best Surrogates. **2015**, 25-43		
11	A patient with hypertension and high cardiovascular risk. *Medicína Pro Praxi*, **2016**, 13, 83-88	0	
10	A new fixed combination of perindopril, indapamide and amlodipine. "Three in one" is the way to improve the results of arterial hypertension treatment. *Systemic Hypertension*, **2017**, 14, 65-68	1.6	
9	Is Hypertension-Related Target Organ Damage Reversible/Preventable?. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 867-880	0.1	
8	Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill. *Vnitrni Lekarstvi*, **2019**, 65, 809-814	0.3	
7	Blood vessel ageing and vascular memory. *Vnitrni Lekarstvi*, **2020**, 66, 104-110	0.3	1

6	Antihypertensive therapy: controlling the processes of replicative cell senescence. *Russian Journal of Cardiology*, 25, 3974	1.3	
5	Perindopril: the evidence of its therapeutic impact in hypertension. *Core Evidence*, **2007**, 2, 63-79	4.9	2
4	Microcirculation and Macrocirculation in Hypertension: A Dangerous Cross-Link?. *Hypertension*, **2022**, HYPERTENSIONAHA12117962	8.5	3
3	Effect of Different Classes of Antihypertensive Drugs on Arterial Stiffness. **2023**, 25, 61-70		0
2	Aging of the Arterial System. **2023**, 24, 6910		0
1	The Ultrasound Window Into Vascular Ageing.		0